验证数据展示
经过测试的应用
| Positive FC detected in | human PBMCs |
推荐稀释比
| 应用 | 推荐稀释比 |
|---|---|
| Flow Cytometry (FC) | FC : 0.25 ug per 10^6 cells in a 100 µl suspension |
| This reagent has been tested for flow cytometric analysis. It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
| Sample-dependent, Check data in validation data gallery. | |
产品信息
65562-1-MR targets CD19 in FC applications and shows reactivity with human samples.
| 经测试应用 | FC Application Description |
| 经测试反应性 | human |
| 免疫原 |
Human chronic lymphocytic leukemia (CLL) cells 种属同源性预测 |
| 宿主/亚型 | Mouse / IgG2a |
| 抗体类别 | Recombinant |
| 产品类型 | Antibody |
| 全称 | CD19 molecule |
| 别名 | 4G7, B lymphocyte antigen CD19, B4, B-lymphocyte antigen CD19, B-lymphocyte surface antigen B4 |
| 计算分子量 | 556 aa, 61 kDa |
| GenBank蛋白编号 | BC006338 |
| 基因名称 | CD19 |
| Gene ID (NCBI) | 930 |
| ENSEMBL Gene ID | ENSG00000177455 |
| RRID | AB_3670316 |
| 偶联类型 | Unconjugated |
| 形式 | Liquid |
| 纯化方式 | Protein A purfication |
| UNIPROT ID | P15391 |
| 储存缓冲液 | PBS with 0.09% sodium azide, pH 7.3. |
| 储存条件 | Store at 2-8°C. Stable for one year after shipment. |
背景介绍
CD19 is a 95 kDa type I transmembrane glycoprotein belonging to the immunoglobulin superfamily (PMID: 2472450). It is expressed by B cells and follicular dendritic cells. CD19 is up-regulated at the step of B-lineage commitment during the differentiation of the hematopoietic stem cell, it remains on during subsequent stages of differentiation until finally down-regulated during terminal differentiation into plasma cells (PMID: 8528044). CD19 is involved in B cell development, activation and differentiation. It is the dominant component for the signaling complex on B cells that includes CD21 (CR2), CD81 (TAPA-1) and CD225 and acts as a critical co-receptor for BCR signal transduction (PMID: 23210908).
实验方案
| Product Specific Protocols | |
|---|---|
| FC protocol for CD19 antibody 65562-1-MR | Download protocol |
| Standard Protocols | |
|---|---|
| Click here to view our Standard Protocols |

